Health
Cancer Vaccine Expected Approval
A personalized cancer vaccine is anticipated to receive approval next year, based on successful late-stage trials that showed reduced recurrence or death rates in patients with skin cancer.
Coverage timeline — 1 article
New Scientist
A bespoke vaccine that is tailored to target an individual's unique skin cancer reduced rates of recurrence or death in a late-stage trial, making an approval expected
2026-10-23 14:42 UTC